Ablynx Builds Case For AbbVie Option On Humira Successor

07 Jul 2016

• By Sukaina Virji

Clinical data shows Ablynx's anti-IL 6R vobarilizumab (ALX0061) to have efficacy in the same range as Roche's Actemra as a monotherapy for rheumatoid arthritis. With more data due shortly, Ablynx is confident that AbbVie will exercise its option for the product.

Ablynx NV's anti-IL 6R nanobody vobarilizumab (ALX-0061) has shown positive results in a Phase IIb monotherapy study in patients with moderately to severely active rheumatoid arthritis (RA) who were intolerant to methotrexate or for whom continued methotrexate treatment was inappropriate.

Topline efficacy data suggest that vobarilizumab appears to be as effective as Roche's IL-6 inhibitor Actemra (tocilizumab), but with...